NDA 020222 · Pfizer
Colestid
Colestipol Hydrochloride · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: May 25, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Jul 19, 1994
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
3 Phase 3, 0 recruiting
FAERS reports
2,659
1,527 serious, 115 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 13, 2025.
INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 19, 1994 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- COLESTID · COLESTIPOL HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Colestipol" as an intervention, any sponsor and status, largest first.
Puma Biotechnology, Inc.Industry
NCT02400476 · 563 participants · Start Feb 2015 · Primary completion Apr 22, 2021
Drug: Neratinib; Loperamide and 2 more · For: Early Stage HER2+ Breast Cancer
Sites: Birmingham, Alabama; Corona, California; Fullerton, California · 58 sites in all
- Effect of the Sequestrant Colesevelam in Bile Acid DiarrhoeaPivotal-lookingCompleted
Lars Kristian MunckAcademic, hospital or other
NCT03876717 · 255 participants · Start Oct 25, 2018 · Primary completion Jul 1, 2021
Drug: Colesevelam Hydrochloride; Placebo oral capsule · For: Bile Acid Malabsorption; Chronic Diarrhea
Sites: Aalborg, Denmark; Aarhus, Denmark; Hvidovre, Denmark · 4 sites in all
- Familial Atherosclerosis Treatment StudyPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00000512 · 146 participants · Start Jan 1984 · Primary completion Aug 1989
Drug: lovastatin; colestipol and 1 more · For: Cardiovascular Diseases; Coronary Arteriosclerosis; Coronary Disease and 2 more
Tuscaloosa Research & Education Advancement CorporationAcademic, hospital or other
NCT00203476 · 30 participants · Start May 2005 · Primary completion Jan 2008
Drug: Niacin; Colestipol and 1 more · For: Hyperlipidemia; Hypercholesterolemia
Sites: Tuscaloosa, Alabama
Derrick Scott RobertsonAcademic, hospital or other
NCT02263547 · 14 participants · Start Mar 2015 · Primary completion Jun 2016
Drug: teriflunomide; Colestipol · For: Teriflunomide Elimination; Healthy Volunteers
Sites: Tampa, Florida
- Sorbent Therapy of the Cutaneous PorphyriasPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT01422915 · 4 participants · Start May 2011 · Primary completion Mar 2012
Drug: Colestipol · For: Erythropoietic Protoporphyria
Sites: Boston, Massachusetts
- Cholesterol-Lowering Atherosclerosis Study (CLAS)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000599 · Start Jun 1980
Drug: colestipol; niacin · For: Arterial Occlusive Diseases; Cardiovascular Diseases; Carotid Artery Diseases and 7 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea380
- off label use288
- nausea233
- fatigue220
- drug ineffective181
- headache145
- vomiting128
- pain127
- weight decreased116
- arthralgia115
- asthenia115
- dizziness112
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 32 |
| 2006 | 24 |
| 2007 | 35 |
| 2008 | 40 |
| 2009 | 68 |
| 2010 | 100 |
| 2011 | 102 |
| 2012 | 130 |
| 2013 | 56 |
| 2014 | 53 |
| 2015 | 86 |
| 2016 | 113 |
| 2017 | 123 |
| 2018 | 155 |
| 2019 | 150 |
| 2020 | 128 |
| 2021 | 163 |
| 2022 | 213 |
| 2023 | 210 |
| 2024 | 236 |
| 2025 | 245 |
| 2026 | 172 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Colestid (Colestipol HCl)
2024 spending
$41K
Beneficiaries
95
200 claims
Per beneficiary
$429
$2.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $301,136 |
| 2021 | $353,580 |
| 2022 | $135,142 |
| 2023 | $199,073 |
| 2024 | $40,759 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Beneficial effect of a bile acid resin binder on enteral feeding induced diarrhea.
DeMeo M, Kolli S, Keshavarzian A, et al. · Am J Gastroenterol 1998 · Clinical Trial, Randomized Controlled Trial
- Statins for children with familial hypercholesterolemia.
Vuorio A, Kuoppala J, Kovanen PT, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Statins for children with familial hypercholesterolemia.
Vuorio A, Kuoppala J, Kovanen PT, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Statins for children with familial hypercholesterolemia.
Vuorio A, Kuoppala J, Kovanen PT, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Adverse effects of hypolipidaemic drugs.
Knodel LC, Talbert RL · Med Toxicol 1987 · Clinical Trial, Comparative Study
- Lipid-lowering agents in proteinuric diseases.
Appel GB, Appel AS · Am J Nephrol 1990 · Clinical Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.